Radium-223 Expanded Access Program with Abiraterone and Enzalutamide - Oliver Sartor

April 10, 2015

*It is recommended to watch this video in full screen for an optimal viewing experience.

Prior and Concurrent Use of Abiraterone and Enzalutamide with Radium-223 in US Expanded Access Setting

Professor Sartor provides results from the US Expanded Access trial that demonstrates radium-223 concurrently administered with abiraterone acetate or enzalutamide is safe and well tolerated.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana

Bibliographical Information

Dr. Oliver Sartor is the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He is a medical oncologist with an interest in prostate cancer from both a basic and clinical perspective. He is on the Department of Defense Integration Panel for prostate cancer research and is the chairman-elect of the organization as well as co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Radiation Oncology Treatment Group Genitourinary Cancer Committee. In addition, Dr. Sartor is a SPORE project co-PI at Dana-Farber Cancer Center on a translational project involving the clinical outcomes and consequences of the 8q24 risk alleles. Dr. Sartor's current research interests include clinical trials in advanced prostate cancer with novel agents and novel combinations of agents. His collaborative projects include novel concepts in prostate stem cells and germ line assessment of prostate cancer risk.